• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.78% Nasdaq Down1.13%

    PDL BioPharma, Inc. (PDLI)

    3.56 Down 0.09(2.47%) 4:00PM EDT
    |After Hours : 3.32 Down 0.24 (6.74%) 5:24PM EDT
    ProfileGet Profile for:
    PDL BioPharma, Inc.
    932 Southwood Boulevard
    Incline Village, NV 89451
    United States - Map
    Phone: 775-832-8500
    Fax: 775-832-8501
    Website: http://www.pdl.com

    Index Membership:N/A
    Full Time Employees:10

    Business Summary 

    PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. PDL BioPharma, Inc. has license agreements with various biotechnology and pharmaceutical companies, as well as acquires royalty and other assets. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on PDL BioPharma, Inc.

    Corporate Governance 
    PDL BioPharma, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 4. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 4; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. John Peter McLaughlin J.D., 64
    Chief Exec. Officer, Pres, Director, Member of Litigation Committee and Member of Compliance Committee
    Mr. Peter S. Garcia , 54
    Chief Financial Officer and VP
    Mr. Steffen Pietzke CPA, 44
    Chief Accounting Officer and Controller
    Mr. Christopher L. Stone J.D., 52
    VP, Gen. Counsel and Sec.
    Mr. Danny J. Hart Jr., J.D., 40
    VP of Bus. Devel.
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders